The case for & against
Bull & Bear analysis
Gilead Sciences, Inc. (NASDAQ: GILD) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapeutics in oncology, HIV, liver diseases, and inflammation. The company is currently positioned as a leader in the HIV treatment market, primarily through products like Biktarvy and the promising injectable prevention product, Yes2Go. Gilead's approach combines innovative therapies in a robust pipeline with strategic acquisition initiatives aimed at enhancing its portfolio and addressing unmet medical needs, particularly in oncology.
Bull says
- ↑HIV product sales rose 10% YoY, underpinning management’s 8% growth outlook.
- ↑FDA approval of Trodelvy in triple-negative breast cancer expands oncology franchise.
- ↑Yes2Go (Lenacapavir) on track for $800M sales in 2026 with 75% payer coverage.
- ↑Pipeline strength: 47 clinical programs and eight additional HIV launches by 2033.
- ↑Q1 product sales reached $6.9B (+5% YoY), operating margin at 47%, $400M returned to shareholders.
- ↑High profitability, strong earnings yield, and robust free cash flow support valuation.
Bear says
- ↓Medicare Part D reform could cut ~$900M in HIV sales, shaving 2% growth.
- ↓Rising competition in HIV and cell therapies risks market share erosion.
- ↓Logistics and adoption delays for Yes2Go may hinder launch ramp.
- ↓Cell therapy revenues likely to decline ~10% YoY amid KITE pressures.
- ↓Low institutional ownership and elevated short interest signal weak confidence.
- ↓Downward analyst revisions and pricing headwinds may pressure earnings.
Investment themes with GILD
Companies paying above-average dividends
Genetic and drug innovations driving medical breakthroughs
Products and services targeting weight management
Earnings Call · Q1 2026 · Mgmt. Guidance